Healthcare Equipment and Supplies
Company Overview of Alcon, Inc.
Alcon, Inc. develops and manufactures eye care products for eye care professionals and their patients. It offers surgical products, which include technologies and devices for cataract, retinal, glaucoma, and refractive surgery; advanced technology intraocular lenses to treat cataracts and refractive errors, such as presbyopia and astigmatism; and advanced viscoelastics, surgical solutions, surgical packs, and other disposable products for cataract and vitreoretinal surgery. The company also provides pharmaceutical products for elevated intraocular pressure caused by glaucoma; anti-inflammatories; anti-infective to aid in the treatment of bacterial infections and bacterial conjunctivitis; oph...
6201 South Freeway
Fort Worth, TX 76134-2001
Founded in 1945
Key Executives for Alcon, Inc.
Chief Operating Officer and Executive Vice President
Region President of Latin America and Canada
Region President of United States
Compensation as of Fiscal Year 2014.
Alcon, Inc. Key Developments
Alcon Receives FDA Approval of Pazeo(TM) Solution for Ocular Allergy Itch Relief
Feb 2 15
Alcon has received approval from the US Food and Drug Administration (FDA) of Pazeo(TM) (olopatadine hydrochloride ophthalmic solution) 0.7%, for the treatment of ocular itching associated with allergic conjunctivitis. Pazeo solution is dosed one drop daily, and was approved with efficacy data at 24 hours, post dose. Results from two Conjunctival Allergen Challenge clinical studies showed that Pazeo (olopatadine hydrochloride ophthalmic solution) 0.7%, demonstrated statistically significantly improved relief of ocular itching associated with allergic conjunctivitis at 24 hours post-treatment compared to olopatadine 0.2% (known as Pataday(R) solution). The safety profile of Pazeo solution is comparable to that of olopatadine 0.2%. In the two clinical studies, the most common adverse reactions occurred in 2 to 5% of patients treated with either Pazeo solution or a vehicle. These events were blurred vision, dry eye, superficial punctate keratitis, dysgeusia and abnormal sensation in the eye.
Alcon Announces Unaudited Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Reports Impairment Charges
Jan 27 15
Alcon announced unaudited earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net sales were USD 2.7 billion against USD 2.66 billion a year ago. Operating income was USD 365 million against USD 172 million a year ago. Core operating income was USD 895 million against USD 851 million a year ago. Net sales led by robust growth in the Ophthalmic Pharmaceuticals and Surgical franchises. Operating income increased 112% driven by strong operating performance and the ending in 2013 of integration charges related to the acquisition of Alcon. Core operating income advanced 5% (+14% cc), driven by higher sales and productivity programs.
For the full year, the company reported net sales were USD 10.83 billion against USD 10.5 billion a year ago. Operating income was USD 1.6 billion against USD 1.23 billion a year ago. Core operating income was USD 3.81 billion against USD 3.69 billion a year ago.
The company reported total impairment charges of USD 1 million for the fourth quarter of 2014.
Google Picks Alcon to Manufacture Smart Contact Lenses
Jul 15 14
Alcon, the eye care division of Novartis, has agreed to license the technology Google has been working on and apply non-invasive sensors, microchips and other miniaturized electronics to a pair of smart contact products. The first product is the one all heard about already, where glucose levels are monitored through teardrops in the eye and reported to a smartphone. The second product is geared at helping farsighted users see better by restoring the eye’s natural ability to focus. These aren’t expected to be features that exist within the same contact lens just yet, but individually these lenses serve to dramatically improve the quality of life for their owners.
Similar Private Companies By Industry
Recent Private Companies Transactions